Actos (pioglitazone): a new treatment for type 2 diabetes

Authors:

Abstract
Type 2 diabetes is increasingly common and can be difficult to control. By directly targeting insulin resistance, the thiazolidinediones offer a new mode of treatment. Here, the pharmacology, clinical trial evidence, side-effects and current clinical uses of pioglitazone are reviewed.

This publication has 15 references indexed in Scilit: